Comparison of standard versus low‐dose valganciclovir regimens for cytomegalovirus prophylaxis in high‐risk liver transplant recipients-Reference-Cited by-同舟云学术

Comparison of standard versus low‐dose valganciclovir regimens for cytomegalovirus prophylaxis in high‐risk liver transplant recipients

Published:2021-08-29 Issue:5 Volume:23 Page:
ISSN:1398-2273
Container-title:Transplant Infectious Disease
language:en
Short-container-title:Transpl Infect Dis

Author:

Bixby Alexandra L.¹^ORCID,Fitzgerald Linda²,Park Jeong M.²³,Kaul Daniel⁴^ORCID,Tischer Sarah²

Affiliation:

1. Department of Pharmacy Services University Hospitals Cleveland Medical Center Cleveland Ohio USA

2. Department of Pharmacy Michigan Medicine Ann Arbor Michigan USA

3. Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan USA

4. Department of Internal Medicine, Division of Infectious Diseases Michigan Medicine Ann Arbor Michigan USA

Publisher

Wiley

Subject

Infectious Diseases,Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tid.13713

Reference24 articles.

1. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

2. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

3. Infection in Organ Transplantation

4. Transplant Infectious Diseases: A Review of the Scientific Registry of Transplant Recipients Published Data

5. Highlights of prescribing information.Hoffmann‐La Roche Limited. Product Monograph Valcyte.2010.http://www.gene.com/gene/products/information/valcyte/pdf/pi.pdf. Accessed July 6 2019.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update;Transplantation Reviews;2024-12

2. Therapeutic Myths in Solid Organ Transplantation Infectious Diseases;Open Forum Infectious Diseases;2024-06-15

3. Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients;Annals of Pharmacotherapy;2024-05-27

4. Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants);Annals of Transplantation;2024-03-15

5. Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients;American Journal of Transplantation;2023-12